TMEM132D-AS2

Across TCGA pan-cancer cohorts, TMEM132D-AS2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated TMEM132D-AS2 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher TMEM132D-AS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM132D-AS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRC show a favorable association.

CHOL, READ, and LUAD are the cancer types where TMEM132D-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.024	0.728	<.001	108	view →
READ	OS	Tertile	II,III,IV	0.111	0.919	<.001	108	view →
LUAD	OS	Tertile	All	0.862	0.667	.009	36	view →
GBM	OS	Tertile	All	0.200	0.428	.037	18	view →
LIHC	OS	Tertile	All	0.173	0.679	<.001	18	view →
PCPG	DFS	Tertile	All	0.586	0.930	.005	18	view →
KIRC	DFS	Tertile	All	0.974	0.865	.015	6	view →
DLBC	DFS	Tertile	All	0.153	0.757	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TMEM132D-AS2–CHOL (OS)

Open the CHOL breakdown →